Boston Scientific (BSX) Stock Plunges to 52-Week Low: Analyst Downgrades Pile Up

Key Takeaways Shares touched a 52-week bottom at $59.32, shedding more than 37% in 2024 First-quarter sales of $5.2 billion exceeded projections, yet annual earnings outlook was trimmed Investors reacted negatively to the Penumbra purchase priced at $374 per share Company faces intensifying competition in the pulsed field ablation market segment Wall Street analysts slashed price objectives while maintaining predominantly positive ratings Shares of Boston Scientific reached their lowest point in a year at $59.32 during Monday’s trading session, marking the culmination of a difficult period that has erased more than 37% of the stock’s value since the beginning of January. Boston Scientific Corporation, BSX The dramatic decline stems from several critical developments that unfolded in rapid succession. The company first revealed its planned acquisition of Penumbra, a medical device manufacturer specializing in neurovascular and peripheral vascular technologies. With a purchase price set at $374 per share, market participants expressed significant displeasure with the transaction terms. Subsequently, the first quarter financial results were released. While the headline figures appeared solid — revenues reached $5.2 billion, representing an 11.6% increase from the prior year period, and adjusted earnings per share of $0.80 surpassed expectations — leadership revised downward its full-year organic revenue growth projection to a range of 6.5–8.0%, below previous estimates. The adjusted earnings per share forecast for the complete fiscal year was also reduced. This recalibration of expectations triggered widespread analyst response. Wall Street Slashes Price Objectives Truist Securities reduced its price objective from $90 down to $85. Canaccord implemented the most aggressive revision, cutting its target from $109 all the way to $71. RBC Capital adjusted downward from $105 to $100, while Jefferies moved from $110 to $100. BTIG lowered its projection to $80 from a previ...